SPX3,911.74+116.01 3.06%
DIA315.02+8.28 2.70%
IXIC11,607.62+375.43 3.34%

BRIEF-Janssen Presents Updated Results Evaluating First-In-Class Gprc5d Bispecific Antibody Talquetamab In Heavily Pretreated Patients With Multiple Myeloma

reuters.com · 06/10/2022 08:11
BRIEF-Janssen Presents Updated Results Evaluating First-In-Class Gprc5d Bispecific Antibody Talquetamab In Heavily Pretreated Patients With Multiple Myeloma

-

  • JANSSEN PRESENTS UPDATED RESULTS EVALUATING FIRST-IN-CLASS GPRC5D BISPECIFIC ANTIBODY TALQUETAMAB IN HEAVILY PRETREATED PATIENTS WITH MULTIPLE MYELOMA

Source text for Eikon: ID:nPn24BJWda


((reuters.briefs@thomsonreuters.com;))